Osteosarcoma and chondrosarcoma are the 2 most common malignant bone tumors. This review discusses the clinicopathologic features, recent preclinical developments, and targets currently being or to be validated in the clinic.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.07.012DOI Listing

Publication Analysis

Top Keywords

osteosarcoma chondrosarcoma
8
update targets
4
targets novel
4
novel treatment
4
treatment options
4
options high-grade
4
high-grade osteosarcoma
4
chondrosarcoma osteosarcoma
4
chondrosarcoma common
4
common malignant
4

Similar Publications

Bone sarcomas and cancer predisposition syndromes.

Bull Cancer

January 2025

Department of Paediatric Oncology, Institut d'Haematologie et d'Oncologie Pédiatrique, Centre Léon-Bérard, Lyon, France. Electronic address:

Bone sarcomas, constituting less than 1% of malignant neoplasms across all age groups, are rare tumours possibly associated with genetic susceptibility syndromes. This review aims to provide recommendations for the detection of cancer predisposition syndromes associated with bone sarcomas and managing affected patients. Recommendations were formulated by a multidisciplinary working and reviewing group from GROUPOS and SFCE oncogenetic's group, including geneticists, oncologists, and radiologists.

View Article and Find Full Text PDF

Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.

Global Spine J

January 2025

Combined Neurosurgical and Orthopedic Spine Program, Department of Orthopedics Surgery, University of British Columbia, Vancouver, BC, Canada.

Study Design: Narrative review.

Objectives: This article aims to provide a narrative review of the current state of research for liquid biopsy in spinal tumors and to discuss the potential application of liquid biopsy in the clinical management of patients with spinal tumors.

Methods: A comprehensive review of the literature was performed using PubMed, Google Scholar, Medline, Embase and Cochrane databases, and the review was limited to articles of English language.

View Article and Find Full Text PDF

The advancement of personalized treatments in oncology has garnered increasing attention, particularly for rare and aggressive cancer with low survival rates like the bone tumors osteosarcoma and chondrosarcoma. This study introduces a novel PDMS-agarose microfluidic device tailored for generating patient-derived tumor spheroids and serving as a reliable tool for personalized drug screening. Using this platform in tandem with a custom imaging index, we evaluated the impact of the anticancer agent doxorubicin on spheroids from both tumor types.

View Article and Find Full Text PDF

A Rare Case of Primary Chondrosarcoma of the Breast: A Case Report and Comprehensive Literature Review.

Discoveries (Craiova)

September 2024

Department of Oncopathology, Homi Bhabha Cancer Hospital (HBCH) and Mahamana Pandit Madan Mohan Malviya Cancer Centre (MPMMCC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Varanasi, India.

Breast sarcomas are a diverse group of malignant neoplasms originating from the mammary stroma. They are uncommon tumors, often occurring as a component of other tumors. Among malignant breast mesenchymal tumors, pure sarcomas lacking epithelial components are even rarer, comprising only 0.

View Article and Find Full Text PDF

Sarcomas of the Head and Neck Region.

J Craniofac Surg

January 2025

Department of Pathology, Pathohistology and Medical Cytology, University Clinical Center of Serbia, Belgrade, Serbia.

Introduction: Sarcomas are relatively rare malignant tumors of mesenchymal origin, representing only about 1% of tumors in the head and neck region.

Materials And Methods: A retrospective study involved patients with sarcomas of the head and neck region who were diagnosed and treated over a 5-year period.

Results: Nine patients were included, 4 men and 5 women.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!